The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Activity of single-agent bevacizumab (B) in patients with metastatic renal cell carcinoma (RCC) previously treated with VEGF- and mTOR-based therapies.
Andrew J. Armstrong
Consultant or Advisory Role - Amgen; Bristol-Myers Squibb
Honoraria - Pfizer
Research Funding - Bristol-Myers Squibb; Novartis; Pfizer
James D. Turnbull
No relevant relationships to disclose
Julien Cobert
No relevant relationships to disclose
Tracy Jaffe
Research Funding - Osiris Medical
Michael Roger Harrison
Honoraria - Novartis
Daniel J. George
Consultant or Advisory Role - Bayer; Genentech; Novartis; Pfizer
Honoraria - Genentech; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Exelixis; GlaxoSmithKline; Novartis; Pfizer